Spots Global Cancer Trial Database for A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor
Official Title: A Phase I Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of The Anti-CLDN18.2 and CD47 Bispecific Antibody AK132 in Advanced Malignant Solid Tumor
Study ID: NCT06166472
Conditions
Interventions
Study Description
Brief Summary: This is A Phase I Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of The anti-CLDN18.2 and CD47 Bispecific Antibody AK132 in Advanced Malignant Solid Tumor
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China
Sun Yat-Sen University Cancer Center, Guangzhou, China, Guangzhou, Guangdong, China
Southern Medical University Nanfang Hospital, Guangzhou, Guangdong, China
The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
Huazhong University of Science and Technology Tongji Medical College Affiliated Union Hospital, Wuhan, Hubei, China
Xiangyang Central Hospital, Xiangyang, Hubei, China
Hunan Provincial Cancer Hospital, Changsha, Hunan, China
Contact Details
Name: Ruihua Xu, M.D.
Affiliation: Name:Sun Yat-Sen University Cancer Center, Guangzhou, China
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
